Clinical trial
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Examine the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Standard Therapy With Primary PCI in Patients Diagnosed as Having an ST Elevation Acute Myocardial Infarction
NCT00078013 is registered in ClinicalTrials.gov with Tanabe Pharma Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Examine the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Standard Therapy With Primary PCI in Patients Diagnosed as Having an ST Elevation Acute Myocardial Infarction
- Lead sponsor
- Tanabe Pharma Corporation
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2003
- Completion date
- August 31, 2004
- Enrollment
- 414
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.